Nachrichten zur Royalty Pharma PLC Aktie

Royalty Pharma Declares Second Quarter 2024 Dividend

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma: Solid Operational Performance

…

Earnings call: Royalty Pharma reports solid growth and portfolio expansion By Investing.com

Earnings call: Royalty Pharma reports solid growth and portfolio expansion…

Royalty Pharma PLC (RPRX) Q4 2023 Earnings Call Transcript

…

Royalty Pharma plc 2023 Q4 - Results - Earnings Call Presentation

…

Royalty Pharma Reports Q4 and Full Year 2023 Results

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma: One Of The Best Names In Pharmaceuticals

…

Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board…

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is…

Royalty Pharma ownership shows strong institutional and insider confidence By Investing.com

Royalty Pharma ownership shows strong institutional and insider confidence…

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop…

Teva signs $125m deal with Royalty Pharma on antipsychotic drug

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to…

Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript

…

Royalty Pharma Reports Third Quarter 2023 Results

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) --  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma to pay $1 billion for Roches SMA drug royalties By Reuters

Royalty Pharma to pay $1 billion for Roches SMA drug royalties…

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with…

Royalty Pharma declares $0.20 dividend

…

Royalty Pharma Declares Fourth Quarter 2023 Dividend

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of…

Royalty Pharma In $500 Million Royalty Pact for Gene Therapy Adstiladrin

Royalty Pharma In $500 Million Royalty Pact for Gene Therapy Adstiladrin...…

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

NEW YORK and SAINT PREX, Switzerland, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and…

Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 1.153.091$

Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-08-10...…

Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 1.151.936$

Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-08-09...…

Compared to Estimates, Royalty Pharma (RPRX) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the…

Royalty Pharma (RPRX) Surpasses Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 2.41% and 1.20%, respectively, for the quarter ended June 2023. Do…

Form 8-K Royalty Pharma plc For: Aug 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Royalty Pharma reports Q2 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Royalty Pharma Q2 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Royalty Pharma (RPRX) Might Surprise This Earnings Season

Royalty Pharma (RPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings…

Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023

NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Royalty Pharma Declares Third Quarter 2023 Dividend

NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 1.165.256$

Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-07-12...…

Insiderhandel: EVP & CFO verkauft Aktien von Royalty Pharma Plc im Wert von 1.159.958$

Coyne, Terrance P. - Vorstand - Tag der Transaktion: 2023-07-13...…

Insiderhandel: CEO, Chairman of the Board kauft Aktien von Royalty Pharma Plc im Wert von 3.836.768$

Legorreta, Pablo G. - Vorstand - Tag der Transaktion: 2023-06-28...…

Form 8-K Royalty Pharma plc For: Jun 22

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Implied Volatility Surging for Royalty Pharma (RPRX) Stock Options

Investors need to pay close attention to Royalty Pharma (RPRX) stock based on the movements in the options market lately....…

S&P 500 Futures Climb in Premarket Trading; Royalty Pharma, Coherent Lead

S&P 500 Futures Climb in Premarket Trading; Royalty Pharma, Coherent Lead...…

Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is…

Insiderhandel: EVP, Investments & CLO verkauft Aktien von Royalty Pharma Plc im Wert von 2.674.796$

Lloyd, George W. - Vorstand - Tag der Transaktion: 2023-06-06...…

Insiderhandel: EVP, Investments & CLO verkauft Aktien von Royalty Pharma Plc im Wert von 3.159.345$

Lloyd, George W. - Vorstand - Tag der Transaktion: 2023-06-02...…

Insiderhandel: EVP, Investments & CLO verkauft Aktien von Royalty Pharma Plc im Wert von 644.446$

Lloyd, George W. - Vorstand - Tag der Transaktion: 2023-06-05...…

Insiderhandel: CEO, Chairman of the Board kauft Aktien von Royalty Pharma Plc im Wert von 4.837.440$

Legorreta, Pablo G. - Vorstand - Tag der Transaktion: 2023-05-24...…

Insiderhandel: Aufsichtsrat verkauft Aktien von Royalty Pharma Plc im Wert von 57.435.000$

Riggs, Rory B. - Aufsichtsrat - Tag der Transaktion: 2023-05-22...…

Royalty Pharma gains as CEO buy over $7M company shares

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: CEO, Chairman of the Board kauft Aktien von Royalty Pharma Plc im Wert von 2.293.096$

Legorreta, Pablo G. - Vorstand - Tag der Transaktion: 2023-05-17...…

Insiderhandel: CEO, Chairman of the Board kauft Aktien von Royalty Pharma Plc im Wert von 5.383.728$

Legorreta, Pablo G. - Vorstand - Tag der Transaktion: 2023-05-16...…

XFRA : DIVIDEND/INTEREST INFORMATION - 18.05.2023 - GB00BMVP7Y09

Das Instrument RPD GB00BMVP7Y09 ROYALTY PHARMA OA DL-0001 EQUITY wird ex Dividende/Zinsen gehandelt am 18.05.2023 The instrument RPD GB00BMVP7Y09 ROYALTY PHARMA…

Royalty Pharma (RPRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended March 2023,…

Royalty Pharma (RPRX) Q1 Earnings and Revenues Top Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 21.21% and 23.65%, respectively, for the quarter ended March 2023. Do…